Tradestie Institutional Equity Comparison Engine

DMAC vs RGNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RGNX at N/M Forward P/E and -120.4% operating margin (-69.2% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
DMAC N/M vs RGNX N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs -120.4% ยท YoY +0.0% vs -69.2%
Momentum & Technical Winner DMAC
1Y +55.3% vs -35.8% ยท 52W Pos 55% vs 19%
Options & Structure Winner DMAC
SURGE (14th %ile IV) vs BREAKDOWN (52nd %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
1M Return +7.87%
1Y Return -35.82%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% RGNX -35.82% Spread: +91.08 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue RGNX Revenue DMAC Op. Margin RGNX Op. Margin Margin Edge
FY2018 $0M $220M -1352.2% 40.3% RGNX
FY2019 N/A $40M N/A -422.9% RGNX
FY2020 N/A $150M N/A -77.1% RGNX
FY2021 N/A $470M N/A 34.0% RGNX
FY2022 N/A $110M N/A -233.2% RGNX
FY2023 N/A $90M N/A -297.1% RGNX
FY2024 N/A $80M N/A -280.0% RGNX
FY2025 N/A $170M N/A -94.6% RGNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (5) vs RGNX (2)
Institutional Metric DMAC RGNX Criterion Row Winner
Market Capitalization Scale $503.1M $500.9M Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -69.2% Higher Growth DMAC
Operating Margin (TTM) Profitability 0.0% -120.4% Higher Margin DMAC
Net Profit Margin Profitability 0.0% -113.9% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -114.6% -113.2% Higher ROE RGNX
52-Week Range Position Momentum 55% ($5โ€“$11) 19% ($5โ€“$16) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 1.81ฮฒ ยท 76% Vol Lower Realized Risk RGNX
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 45.3 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs RGNX Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor RGNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.